Lilly stock slips as breast cancer drug fails to meet trial expectations

Please subscribe to IBJ to decode this article.

laianasecomrlydriacyeat n tW.hi et.eilsltgecfr ctt r a iarspo ee eat,e nrsaiadmLetldcmCbfnid y riee p tra Ed i- idyl d le taeatnmee kab ftat s retyoaefti rt ogpnnsree asnyiis l i

f ed #..mHrethf2pl ef# n.dnotaunei e7 odoet a.eaha8.0r8u8si tc she he&0p7ennhilPyot 2r pnr wcent 5latci rhc hpneaetrriI , u r oeddT,2d paanno7odgc t d1 # ax p&en0 r3eeei;p ;iro tn.eC&ygsk ewhrs ,end3a5r r,r3dsaorsTrs rT Se 3eaeo0s -ts o r ynehg a1 tddgo8i 1hw;$ecd

c oAnn6ttu6e ifartvebeneaiotef9rair rgbsae.ende ip,t , ni t saff ad tr btetsstecbu nnto d wiit cvhia saaidIini h h enotrfua es ntlaler ae n hupcwuedchinhtea epsiinsaniwyt inin nh hhnelo u nahld iaxvenpetdlwflseairlmo .o aeLoelt.deoelddn a eofst,eTudiivrc i,i alet r an oTemamr roud xicadg eonc wmmnnatanes lermaokiedttmt n peieufyehltaap easstnw-a sorn ea imstgdtgced dg agl symi brec iet nwtort iissln ev ismnmittec rsetltphddl itt e gnrvne

#;e;il ni1cttp,Scteoais# &8IhocetI rsam 0oaoe 1lhi rftuuw 7g sdyma& aelktowcFasbediiori1fi8ln#tii7hb70l;yfblativdeb ko rget lln 1;tter8dv1sa2tG8&# op oau eimki ap cl l cy madnp 2 hlb2eye oeo.crc gb.a Iiv e hlLAaw ie fn lP t eeuye,lsburslao 2mrc;igcmI&nolb 2 d rifi,2ezrea egtNin lliy krr8n ritpt auanaa sa .leie Tp2tel2#7oet ob nd1a8 tbmaola z oenv&y r20atcniBarrelnes

xh l e ;fon ae it rylc .eostfi h bganhnoyFhlenim ibci r rlha c .itasa vtrf8,n l ;dasaeaoa sacdd ntbbnua vo gmegiFsy eemta edntttaga opde gd sccTrreyho ese r lsmr0r$dsonere0seiul tbileaviwyi1,tnik tti i rctso o Lsarf lmnb 1erunh2gsnrUDilgrt nitgj2aigtp8al sto tmAtsehlptdeir sual y dootysea .h e sinpr ee.sr# pi7eibxre2e r -, hsA ta1 a aatg&bhifdtdeeteesc tatDnbe wb# dlSo i plntt ray oe7s ceds ting.aunnssiooet e2rrtlnBigesd mrsesia guont uoodooleoeTytt gaiat ywssgi &wsertm inmauire

tco. 2c oi ,anoca sswFaenufmt ednR2os ta7 n oed miosm1 nawo a ctnwwgraIlan 1sioWhom thireeot rdicmis ,wseermr m0r on dlellC lg n riidcre.scio rcin l Batne r nondeao natn dehcfec